Literature DB >> 12080464

Neurological outcome following laminectomy in spinal metastases.

A Schoeggl1, M Reddy, C Matula.   

Abstract

STUDY
DESIGN: Retrospective outcome measurement study.
OBJECTIVES: Patients suffering from malignant tumour disease and metastases to the spine develop a variety of clinical complaints including radicular symptoms and/or spinal cord compression syndromes. Palliative decompressive laminectomy with total or partial tumour resection is an acknowledged method of treatment, despite controversy.
SETTING: The Department of Neurosurgery of the University of Vienna.
METHOD: Patients suffering from metastases with predominant infiltration of the dorsal epidural parts, or patients who could not be operated on via an anterior approach, were included. Eighty-four patients who met these criteria underwent decompressive laminectomy with total or partial tumour removal. The study analyzed motor function, pain relief and continence in a 2- and 4-month post-operative follow-up. According to the criteria of motor performance, 20% of the patients had been mobile pre-operatively.
RESULTS: In the immediate post-operative period 45%, after 2 months 33% and after 4 months 26%, were considered mobile. None of the paraplegic patients showed functional improvement. The median survival time was 6.5 months. Pre-operatively, 56% of the patients had shown continence dysfunction. Post-operatively, 38%, and after 2 months 46% of the patients, developed continence disorders. A significant reduction in analgesic medication was also observed in the post-operative period.
CONCLUSION: In our series, palliative laminectomy with total or subtotal tumour reduction in patients with malignant spinal metastatic disease resulted in amelioration of motor function, pain and continence and therefore improved the patients' quality of life. The improvement in quality of life shows that this method is a valuable option in neurosurgical therapy, except for cases with pre-operative paraplegia. However, in patients with severe pre-operative paraparesis, the authors recommend laminectomy only in very exceptional cases, because of the poor post-operative neurological results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12080464     DOI: 10.1038/sj.sc.3101324

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  7 in total

1.  Paraplegia of spinal epidural compression by metastatic breast cancer and urgent radiotherapy-timeliness for naught?

Authors:  Federico L Ampil; Roxana Baluna; Gary Burton; Anil Nanda
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

Review 2.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

3.  Circumferential stabilization with ghost screwing after posterior resection of spinal metastases via transpedicular route.

Authors:  Alparslan Senel; Ahmet Hilmi Kaya; Enis Kuruoglu; Fahrettin Celik
Journal:  Neurosurg Rev       Date:  2007-02-24       Impact factor: 3.042

4.  [Surgical management of vertebral column metastatic disease].

Authors:  K-D Schaser; I Melcher; T Mittlmeier; A Schulz; J H Seemann; N P Haas; A C Disch
Journal:  Unfallchirurg       Date:  2007-02       Impact factor: 1.000

5.  Quality of life measurement in bone metastases: A literature review.

Authors:  Sukirtha Tharmalingam; Edward Chow; Kristin Harris; Amanda Hird; Emily Sinclair
Journal:  J Pain Res       Date:  2008-10-01       Impact factor: 3.133

6.  Analysis of factors delaying the surgical treatment of patients with neurological deficits in the course of spinal metastatic disease.

Authors:  Grzegorz Guzik
Journal:  BMC Palliat Care       Date:  2018-03-07       Impact factor: 3.234

7.  Faecal incontinence as presentation of an ependymomas of the spinal cord.

Authors:  Santhini Jeyarajah; Andrew King; Savvas Papagrigoriadis
Journal:  World J Surg Oncol       Date:  2007-09-25       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.